Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation

Amit Sharma, Eun Joong Kim, Hu Shi, Jin Yong Lee, Bong Geun Chung, Jong Seung Kim

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)

Abstract

The high incidence of colorectal cancer worldwide is currently a major health concern. Although conventional chemotherapy and surgery are effective to some extent, there is always a risk of relapse due to associated side effects, including post-surgical complications and non-discrimination between cancer and normal cells. In this study, we developed a small molecule-based theranostic system, Gal-Dox, which is preferentially taken up by colon cancer cells through receptor-mediated endocytosis. After cancer-specific activation, the active drug Dox (doxorubicin) is released with a fluorescence turn-on response, allowing both drug localization and site of action to be monitored. The therapeutic potency of Gal-Dox was also evaluated, both in vivo and ex vivo, thus illustrating the potential of Gal-Dox as a colorectal cancer theranostic with great specificity.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalBiomaterials
Volume155
DOIs
Publication statusPublished - 2018 Feb 1

Keywords

  • Colon cancer
  • Doxorubicin
  • Targeted drug delivery
  • Theranostic
  • β-Galactosidase

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Fingerprint Dive into the research topics of 'Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation'. Together they form a unique fingerprint.

Cite this